<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966898</url>
  </required_header>
  <id_info>
    <org_study_id>SHR6390-III-302</org_study_id>
    <nct_id>NCT03966898</nct_id>
  </id_info>
  <brief_title>A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer</brief_title>
  <official_title>A Phase III Study to Evaluate Efficacy and Safety of SHR6390 in Combination With Letrozole or Anastrozole Versus Placebo in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III clinical trial to evaluate the efficacy and safety of SHR6390 in
      combination with Letrozole or Anastrozole versus placebo in combination with Letrozole or
      Anastrozole in Patients who have HR positive and HER2 negative recurrent/metastatic breast
      cancer and have not received systemic anticancer therapy are eligible for this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SHR6390 in combination with Letrozole or Anastrozole versus placebo in combination with Letrozole or Anastrozole</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator-assessed PFS</measure>
    <time_frame>Every 8 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, Up to approximately 24 months.</time_frame>
    <description>Investigator-assessed Progression Free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) per RECIST 1.1</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Duration of Objective Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBR</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Clinical Benefit rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With adverse events (AEs) and serious adverse events (SAEs) Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Number of Participants With adverse events and serious adverse events Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ctrough</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>To explore the pharmacokinetic characteristics of SHR6390 population and the influencing factors</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">426</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SHR6390, Letrozole or Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR6390, Letrozole or Anastrozole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Letrozole or Anastrozole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, Letrozole or Anastrozole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR6390 Tablets</intervention_name>
    <description>SHR6390 Tablets</description>
    <arm_group_label>SHR6390, Letrozole or Anastrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablets</intervention_name>
    <description>Placebo Tablets</description>
    <arm_group_label>Placebo, Letrozole or Anastrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole or Anastrozole Tablets</intervention_name>
    <description>Letrozole or Anastrozole Tablets</description>
    <arm_group_label>Placebo, Letrozole or Anastrozole</arm_group_label>
    <arm_group_label>SHR6390, Letrozole or Anastrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has the pathologically-confirmed diagnosis of locally recurrent or metastatic,
             hormone-receptor positive, HER2 negative Breast Cancer.

          2. Age: 18 - 75 years old

          3. No prior systemic anti-cancer therapy for advanced HR+ disease.

          4. Eastern Cooperative Oncology Group [ECOG] 0-1

        Exclusion Criteria:

          1. Patients who received prior treatment with any CDK4/6 inhibitor.

          2. Clinically significant cardiovascular and cerebrovascular diseases, including but not
             limited to severe acute myocardial infarction within 6 months before enrollment,
             unstable or severe angina, Congestive heart failure (New York heart association (NYHA)
             class &gt; 2), or ventricular arrhythmia which need medical intervention.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xiaoyu Zhu, MD</last_name>
    <phone>+86 021-61053363</phone>
    <email>zhuxiaoyu@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>NAYIMA BAYAXI</last_name>
    <phone>+86 021-61053363</phone>
    <email>nayima.bayaxi@hrglobe.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nayima Bayaxi</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NAYIMA BAYAXI</last_name>
      <phone>+86 021-61053363</phone>
      <email>nayima.bayaxi@hrglobe.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

